S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
S&P 500   3,790.93 (+3.06%)
DOW   30,316.32 (+2.80%)
QQQ   282.00 (+3.10%)
AAPL   145.91 (+2.43%)
MSFT   248.82 (+3.36%)
META   140.28 (+1.20%)
GOOGL   101.61 (+3.01%)
AMZN   121.08 (+4.49%)
TSLA   248.95 (+2.70%)
NVDA   131.70 (+5.26%)
NIO   16.69 (+7.75%)
BABA   84.13 (+4.57%)
AMD   67.81 (+2.57%)
T   16.09 (+1.19%)
MU   53.97 (+4.35%)
CGC   3.13 (+7.56%)
F   12.32 (+7.41%)
GE   67.54 (+6.19%)
DIS   101.46 (+4.46%)
AMC   7.73 (+12.35%)
PYPL   92.82 (+6.47%)
PFE   44.46 (+0.72%)
NFLX   240.88 (+0.77%)
NASDAQ:DARE

Daré Bioscience - DARE Stock Forecast, Price & News

$1.06
+0.02 (+1.44%)
(As of 10/4/2022 03:59 PM ET)
Add
Compare
Today's Range
$1.03
$1.09
50-Day Range
$1.00
$1.26
52-Week Range
$0.92
$2.51
Volume
4,908 shs
Average Volume
282,274 shs
Market Capitalization
$89.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Daré Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
741.1% Upside
$9.00 Price Target
Short Interest
Healthy
1.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Daré Bioscience in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.30) to ($0.37) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

877th out of 1,087 stocks

Pharmaceutical Preparations Industry

432nd out of 546 stocks

DARE stock logo

About Daré Bioscience (NASDAQ:DARE) Stock

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Stock News Headlines

DARE Daré Bioscience, Inc.
Daré Bioscience to Participate in Two Upcoming Conferences
Dare to be different
Dare to be optimistic
Dare Bioscience GAAP EPS of $0.00, revenue of $10M
North Wales: Time to say no to DARE?
See More Headlines
Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Company Calendar

Last Earnings
11/10/2021
Today
10/04/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DARE
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+373.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-38,700,000.00
Pretax Margin
-301.94%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.51 per share

Miscellaneous

Free Float
81,428,000
Market Cap
$89.49 million
Optionable
Not Optionable
Beta
1.24

Key Executives

  • Ms. Sabrina Martucci Johnson (Age 55)
    Pres, CEO, Sec. & Director
    Comp: $643.48k
  • Ms. Lisa Walters-Hoffert (Age 63)
    Chief Financial Officer
    Comp: $439.33k
  • Mr. John A. Fair (Age 50)
    Chief Strategy Officer
    Comp: $435.83k
  • Mr. Mark Walters (Age 67)
    VP of Operations
  • Ms. MarDee J. Haring-Layton (Age 46)
    VP of Accounting & Fin.
  • Dr. David Friend
    Chief Scientific Officer













DARE Stock - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DARE shares.
View DARE analyst ratings
or view top-rated stocks.

What is Daré Bioscience's stock price forecast for 2022?

3 equities research analysts have issued twelve-month price targets for Daré Bioscience's stock. Their DARE share price forecasts range from $4.00 to $17.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 741.1% from the stock's current price.
View analysts price targets for DARE
or view top-rated stocks among Wall Street analysts.

How have DARE shares performed in 2022?

Daré Bioscience's stock was trading at $2.00 at the beginning of the year. Since then, DARE stock has decreased by 46.5% and is now trading at $1.07.
View the best growth stocks for 2022 here
.

When is Daré Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our DARE earnings forecast
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. During the same period in the previous year, the business posted ($0.24) EPS.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How do I buy shares of Daré Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $1.07.

How much money does Daré Bioscience make?

Daré Bioscience (NASDAQ:DARE) has a market capitalization of $90.76 million. The biotechnology company earns $-38,700,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544.

This page (NASDAQ:DARE) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.